Although activating mutations of B-Raf are the most common genetic abnormalities in human melanomas 1 , the mechanism by which mutant B-Raf transforms melanocytes is poorly understood. Here we show that the retinoblastoma tumor suppressor protein (pRB) is a direct target of B-Raf and is inactivated by phosphorylation in melanomas carrying B-Raf mutations. In contrast, pRB is undetectable in melanomas with wild-type B-Raf. Mutant B-Raf directly interacts with pRB and induces its phosphorylation at serine-249 and threonine-252 (S249/T252). Inhibition of B-Raf activity results in dephosphorylation of pRB at S249/T252 along with other sites in melanoma cells. S249/T252 are phosphorylated earlier than other sites during cell cycle entry of normal melanocytes. Blocking B-Raf activation precluded S249/T252 phosphorylation in mitogen-stimulated melanocytes, which was accompanied by the impaired phosphorylation of pRB at other sites. B-Raf enhanced CDK2-mediated pRB phosphorylation in an in vitro kinase assay. These results suggest that B-Raf is an initiating RB kinase, which triggers inactivation of pRB at the earliest step in the cell cycle entry of normal melanocytes, and its activating mutations cause deregulated growth, leading to the development of melanoma.
light such as those on the trunk, arms, and legs, which rarely show the amplification of Cyclin D1 and CDK4. In contrast, B-Raf has wild-type configuration in the vast majority of melanomas from sun-damaged skin, typically on the face, and those with minimal or no UV exposure (acral and mucosal melanomas). Instead, these melanomas often harbor multiple chromosome abnormalities including loss of chromosome 13, deletion of the Ink4a locus, and CDK4/Cyclin D1 amplification, all of which result in physical or functional inactivation of pRB 8 .
The absence of genetic abnormalities directly causing pRB inactivation suggests another mechanism of inactivation in melanomas carrying B-Raf mutation, because the RB-E2F
pathway plays a crucial role in melanocyte differentiation 9 and is altered in almost all melanoma cells 10 , especially those of acral and mucosal origin 11 .
To address this issue, we first investigated the relationship between B-Raf mutation and pRB expression using 10 melanoma cell lines and 11 samples from primary lesions of patients with malignant melanoma. As shown in Fig. 1A , pRB expression was absent or under the detection limit of immunoblotting in 5 out of 10 melanoma cell lines, whereas normal human epidermal melanocytes (NHEM) readily expressed RB protein. In 5 cell lines with intact pRB expression, RB protein was heavily phosphorylated at multiple sites including S249/T252 and serine-780 (Ser780). We concomitantly examined the presence of B-Raf mutations, and found that T1796A substitution of the BRAF gene, which results in a V599E amino acid change, was detected in 6 of the 10 cell lines, whereas there were no mutations in other portions of exon 15, nor anywhere in exon 11 (data not shown). Interestingly, the cell lines harboring B-Raf mutation, except for Malme-3M, expressed intact RB protein, whereas all the cell lines without B-Raf mutation lacked pRB expression (Fig. 1A) . The correlation between B-Raf mutation and pRB expression was also observed in primary samples (Fig. 1B shows representative results and the data from all cases are summarized in Table 1 ). These results indicate that pRB is inactivated in almost all melanoma cells by two mechanisms:
hyperphosphorylation in B-Raf mutation-positive cases and loss of protein expression in BRaf mutation-negative cases.
The coexistence of B-Raf mutation and pRB phosphorylation strongly suggests that Raf kinase inhibitor 12, 13 , and examined the changes in the phosphorylation status of pRB.
The Raf kinase inhibitor almost completely abrogated pRB phosphorylation at multiple sites including S249/T252 and Ser780 with similar kinetics and extent to the effect on ERK1/2, a bona fide target of B-Raf ( Fig. 2A shows the data from MM-RU cells). Cell cycle analysis revealed that G1 arrest was not yet apparent at 24 hours of treatment, when pRB phosphorylation was completely abrogated, indicating that this effect was not a simple consequence of growth arrest ( Fig. 2A) . As GW5074 targets all members of the Raf family 12, 13 , we performed the same experiment using siRNA against B-Raf. Treatment of MM-Ac and G-361 cells with BRAF siRNA reduced the amounts of phosphorylated species of pRB in proportion to the decrease in the abundance of B-Raf protein (Fig. 2B) . It is of note that c-Raf, which was not affected by siRNA against B-Raf, is not able to substitute BRaf for pRB phosphorylation in melanoma cells.
Although these results clearly show that B-Raf is involved in pRB phosphorylation in melanoma cells, it is uncertain whether this effect is direct. To clarify this point, we first examined whether B-Raf physically interacts with pRB in melanoma cells. Coimmunoprecipitation assays revealed that B-Raf and pRB formed a complex in MM-Ac cells, which express mutant B-Raf and intact pRB, whereas the association of the two molecules was not detectable in MM-LH cells, which express normal B-Raf but lack pRB (Fig. 2C ).
Furthermore, we demonstrated the colocalization of B-Raf and pRB using confocal microscopy ( Fig. 2D) . Interestingly, the association was observed both in the nuclei and the cytoplasm, implying that B-Raf plays a role in the nuclear export of pRB, another possible mechanism of functional inactivation 14, 15 .
To corroborate that mutant B-Raf directly phosphorylates pRB, we carried out two types of in vitro kinase assays. First, B-Raf was immunoprecipitated from melanoma cells expressing wild-type B-Raf (MM-LH and RPM-MC) and those expressing mutant B-Raf (MM-Ac and G-361), and subjected to an in vitro kinase assay using highly-purified fulllength pRB as a substrate. Mutant B-Raf exhibited strong RB kinase activity, which was comparable to that of purified CDK2/Cyclin A complex, whereas the normal counterpart possessed a relatively weak activity (Fig. 3A) . Next, we performed the same assay with a combination of recombinant mutant B-Raf kinase (V599E) and purified RB protein, and confirmed the strong activity of mutant B-Raf against pRB, whose specificity was demonstrated by complete inhibition with the Raf inhibitor GW5074 ( , and CDK2/Cyclin E phosphorylates Ser608 and Ser612 at late G1 19, 20 . To data, however, little is known about the biological significance of and kinases responsible for S249/T252 phosphorylation.
Phosphorylation at S249/T252 coincided with the activation of B-Raf, as judged by increased expression and autophosphorylation (Fig. 4B) . Blocking B-Raf activation by the Raf inhibitor GW5074 precluded S249/T252 phosphorylation of pRB in mitogen-stimulated melanocytes, which was accompanied by impaired phosphorylation of pRB at other sites including S780 (Fig. 4C) . These results indicate that B-Raf-mediated pRB phosphorylation at S249/T252 occurs very early during the G0/G1 to S phase transition of normal human melanocytes, and may positively affect the later step of pRB phosphorylation catalyzed by CDK/Cyclin complexes. To test the latter notion, we phosphorylated pRB with B-Raf in the presence of cold ATP, and then subjected the pre-phosphorylated pRB to in vitro kinase assay with purified CDK2/Cyclin A complex. As shown in Fig. 4D 
Cell cycle analysis
The cell cycle profile was obtained by staining DNA with propidium iodide in preparation for flow cytometry analysis with the FACScan/CellQuest system (Becton-Dickinson, San Jose, CA). The size of the sub-G1, G0/G1, and S+G2/M fractions was calculated as a percentage by analyzing DNA histograms using the ModFitLT 2.0 program (Verity Software, Topsham, ME).
Detection of B-Raf mutations
DNA was isolated from melanoma cell lines and primary samples according to the standard methods. Exons 11 and 15 of B-Raf cDNA were amplified by PCR using the following primer pairs: exon 11, sense 5'-TCCCTCTCSGGCATAAGGTAA-3' and antisense 5'-CGAACAGTGAATATTTCCTTTGAT-3'; exon 15, sense 5'-TCATAATGCTTGCTCTGAT AGGA-3' and antisense 5'-GGCCAAAAATTTAATCAGTGGA-3'. PCR products were subjected to direct DNA sequencing after purification.
Immunological procedures
We performed Western blotting, immunoprecipitation-immunoblotting assays, and immunohistochemistry using confocal laser microscopy as previously described 23 
Identification of phosphorylation sites of pRB by nano ESL-MS analysis
Highly-purified full-length RB protein (QED Bioscience, San Diego, CA, USA) was Figure Legends A point mutation at nt. 1796 (T to A substitution) was detected in 2 out of 2 cases with pRB expression (#0682 and #2687), whereas the BRAF gene was in wild-type configuration in 8 out of 9 cases lacking pRB expression (#4190 and #51919, data not shown for other cases).
See Table 1 for summary. 
